Key facts
- It has raised $32.7M across 2 recorded rounds; the latest was Seed Round ($3.1M) in Jan 2019.
- Notable investors include Coefficient Giving, For Good Ventures.
- VasoRx has filed 2 Form Ds with the SEC since 2018, most recently Mar 2019 ($3.1M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for VasoRx
Funding rounds
2 roundsAbout VasoRx
Developer of RNA (Ribonucleic acid) therapies intended to treat diseases of the cardiovascular system, as well as oncology. The company utilises novel nanoparticles that are made of low molecular weight polyamines and lipids that can deliver the RNAs to endothelial cells, enabling the healthcare sector to provide RNA therapeutics and medicines for better treatment of diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Website
- vasrx.com/
- Ownership
- Privately Held (backing)
VasoRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VasoRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VasoRx in its N-PORT filings yet. We sweep new filings monthly.